Table 3.
Average total nightly dose of LXB during SDP, time to reach stable total nightly dose, and number of LXB dose adjustments in participants who achieved a stable dose of LXB, by treatment at study entry (efficacy population)
| Group A | Group B | Group C | Group D | Total (N = 134) | |
|---|---|---|---|---|---|
| SXB only (n = 41) | SXB + other anticataplectics (n = 14) | Other anticataplectics (n = 21) | Anticataplectic naive (n = 58) | ||
| Average total nightly dose of LXB (g/night) | |||||
| Mean | 7.6 | 8.3 | 7.4 | 6.9 | 7.3 |
| SD | 1.4 | 1.1 | 1.3 | 1.5 | 1.4 |
| Median | 7.5 | 9.0 | 7.5 | 7.0 | 7.5 |
| Minimum, maximum | 4.5, 9.0 | 6.0, 9.0 | 4.5, 9.0 | 3.0, 9.0 | 3.0, 9.0 |
| Time to reach stable total nightly dose (days) | |||||
| Mean | 14.5 | 15.7 | 45.5 | 39.0 | 30.1 |
| SD | 21.37 | 24.59 | 18.57 | 20.86 | 24.56 |
| Median | 1.0 | 1.0 | 50.0 | 36.5 | 29.0 |
| Minimum, maximum | 1, 84 | 1, 64 | 5, 73 | 1, 81 | 1, 84 |
| Number of dose adjustments to reach stable total nightly dose | |||||
| Mean | 1.0 | 0.8 | 3.5 | 2.6 | 2.1 |
| SD | 1.99 | 1.48 | 1.47 | 1.35 | 1.87 |
| Median | 0.0 | 0.0 | 3.0 | 3.0 | 2.0 |
| Minimum, maximum | 0, 8 | 0, 5 | 1, 7 | 0, 6 | 0, 8 |
LXB lower-sodium oxybate, SD standard deviation, SDP stable-dose period, SXB sodium oxybate